GlassScriptPhysician profile
Daniel P Gustkey
NPI 1962896241
$11,745.78
in general payments reported to CMS, 2019-2025
35 companies · $3,189 in 2025
The $3,189 reported for 2025 was more than what 83% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $128 · 2023: $1,519 · 2024: $6,911 · 2025: $3,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,306 · Travel and Lodging: $2,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,305.81 |
| Travel and Lodging | $2,312.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,864.25 | 2022-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Neuropace, INC. | $1,670.26 | 2024-2025 | |
| Ucb, INC. | $1,420.20 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $1,297.99 | 2023-2025 | Epidiolex |
| Sk Life Science, INC. | $1,043.90 | 2023-2025 | |
| Biocodex, INC. | $485.23 | 2024-2025 | |
| Neurelis, INC. | $384.94 | 2022-2025 | Valtoco |
| Upsher-Smith Laboratories LLC | $379.45 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $296.42 | 2023-2025 | Daybue |
| Corium, LLC | $257.68 | 2023-2025 | Azstarys |
| Otter Pharmaceuticals, LLC | $251.87 | 2024-2025 | Sympazan |
| Aucta Pharmaceuticals, INC. | $182.65 | 2024-2025 | Motpoly Xr |
| Vertical Pharmaceuticals, LLC | $140.58 | 2024-2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $109.70 | 2023-2024 | Jornay Pm |
| Pyros Pharmaceuticals, INC. | $101.70 | 2024 | Vigpoder |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $93.22 | 2024-2025 | |
| Tris Pharma INC | $85.80 | 2024-2025 | Dyanavel Xr |
| Biogen, INC. | $85.13 | 2024-2025 | Skyclarys |
| Supernus Pharmaceuticals, INC. | $59.46 | 2025 | Qelbree |
| Catalyst Pharmaceuticals, INC. | $59.14 | 2024-2025 | |
| Avion Pharmaceuticals | $58.43 | 2023-2024 | Methylphenidate Hydrochloride |
| Springworks Therapeutics, INC. | $53.24 | 2025 | Gomekli |
| Noven Therapeutics, LLC | $44.55 | 2025 | Xelstrym |
| Amgen INC. | $40.14 | 2023 | Enbrel |
| Janssen Biotech, INC. | $35.35 | 2025 | Tremfya |
| Azurity Pharmaceuticals, INC. | $33.61 | 2025 | Zonisade |
| Collegium Pharmaceutical, INC. | $33.05 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $29.30 | 2025 | Elaprase |
| Immedica Pharma US, INC. | $29.21 | 2024 | |
| Itf Therapeutics LLC | $24.93 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $22.16 | 2025 | Dysport |
| Alexion Pharmaceuticals, INC. | $21.98 | 2023 | Koselugo |
| Octapharma USA, INC. | $19.05 | 2025 | Panzyga |
| Neos Therapeutics, LP | $16.39 | 2024 | Adzenys Xr-Odt |
| Sarepta Therapeutics, INC. | $14.82 | 2024 | Elevidys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gustkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.